Skip header and navigation

9 records – page 1 of 1.

Access to information regarding drug costs

https://policybase.cma.ca/en/permalink/policy9273
Date
2008-Aug-20
Topics
Population health/ health equity/ public health
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association recommends that physicians be provided with ready access to information regarding drug costs so these may be factored into decisions regarding patient care.
Policy Type
Policy resolution
Last Reviewed
2015-Feb-28
Date
2008-Aug-20
Topics
Population health/ health equity/ public health
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association recommends that physicians be provided with ready access to information regarding drug costs so these may be factored into decisions regarding patient care.
Less detail

Cannabis for Medical Purposes

https://policybase.cma.ca/en/permalink/policy10045
Date
2010-Dec-04
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Chalk River National Research Universal reactor

https://policybase.cma.ca/en/permalink/policy9919
Date
2010-Aug-25
Topics
Health systems, system funding and performance
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the federal government to make a public commitment to keep the Chalk River National Research Universal reactor operational for as long as necessary beyond the announced date of 2016 and until secure alternative supplies of isotopes or alternative radiopharmaceuticals are proven and available.
Policy Type
Policy resolution
Last Reviewed
2017-Mar-04
Date
2010-Aug-25
Topics
Health systems, system funding and performance
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the federal government to make a public commitment to keep the Chalk River National Research Universal reactor operational for as long as necessary beyond the announced date of 2016 and until secure alternative supplies of isotopes or alternative radiopharmaceuticals are proven and available.
Less detail

CMA Letter to the Senate Committee on Legal and Constitutional Affairs regarding Bill C-2, An Act to amend the Criminal Code and to make consequential amendments to other Acts

https://policybase.cma.ca/en/permalink/policy9110
Date
2008-Feb-19
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

CMA Submission to the House of Commons Standing Committee on Health - regarding Post-Market Surveillance of Pharmaceutical Products

https://policybase.cma.ca/en/permalink/policy9112
Date
2008-Feb-28
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Health Canada consultation on edible cannabis, extracts & topicals

https://policybase.cma.ca/en/permalink/policy14020
Date
2019-Feb-20
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Population health/ health equity/ public health
  1 document  

Health Canada consultation on reducing youth access and appeal of vaping products

https://policybase.cma.ca/en/permalink/policy14078
Date
2019-May-24
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Population health/ health equity/ public health
  1 document  

Natural health products

https://policybase.cma.ca/en/permalink/policy9255
Date
2008-Aug-20
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the federal minister of health to prohibit claims of the therapeutic value of natural health products for the treatment of diseases listed in Schedule A of the Food and Drug Act when the supportive evidence does not meet the evidentiary standard required of medications regulated by the Health Products and Food Branch of Health Canada.
Policy Type
Policy resolution
Last Reviewed
2015-Feb-28
Date
2008-Aug-20
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the federal minister of health to prohibit claims of the therapeutic value of natural health products for the treatment of diseases listed in Schedule A of the Food and Drug Act when the supportive evidence does not meet the evidentiary standard required of medications regulated by the Health Products and Food Branch of Health Canada.
Less detail

A Prescription for Optimal Prescribing

https://policybase.cma.ca/en/permalink/policy10016
Date
2010-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

9 records – page 1 of 1.